CAPRICOR THERAPEUTICS INC (CAPR)
Health Care · cell and exosome-based therapeutics for rare genetic diseases · NASDAQ
Capricor is a clinical-stage biotech developing cell and exosome therapies for rare genetic disorders, with its lead candidate Deramiocel under FDA review for Duchenne muscular dystrophy treatment.
What CAPRICOR THERAPEUTICS INC does
Capricor Therapeutics is a biotechnology company developing cell and exosome-based therapeutics for rare diseases with significant unmet medical need. The company's lead product, Deramiocel, is a cell therapy comprised of cardiosphere-derived cells (CDCs) designed to treat Duchenne muscular dystrophy (DMD) by addressing cardiac and skeletal muscle complications through immunomodulatory, anti-inflammatory, and anti-fibrotic activities. Deramiocel is currently under FDA review with a PDUFA target action date of August 22, 2026. The company is also advancing its exosome platform (StealthX) for infectious diseases, monogenic diseases, and other potential indications through collaborations with the NIH, NIAID, Johns Hopkins, and others.
Themes: ["cell therapy / regenerative medicine","Duchenne muscular dystrophy (DMD)","exosome therapeutics","rare genetic diseases","immunomodulation"]
Fundamentals
- Price$22.50 as of 2026-07-09 close
- Market cap$1.3B as of 2026-07-10
- 1-year return+97.0% as of 2026-07-09 close
- Net margin-181.7% as of 2026-07-10
- ROE-59.3% as of 2026-07-10
- Debt / equity0.02 as of 2026-07-10
- Beta0.35 as of 2026-07-10
Key risks (from latest filing)
["FDA regulatory approval risk: Deramiocel's BLA is under FDA review with PDUFA target date of August 22, 2026; approval is not certain and delays or rejection would significantly impact commercialization prospects.","Commercial and litigation risk: Company is engaged in litigation with Nippon Shinyaku regarding Deramiocel distribution rights; outcome could materially affect the company's ability to commercialize Deramiocel in the United States.","Liquidity and financing risk: Company is unprofitable with significant ongoing losses; ability to fund operations depends on successful commercialization of Deramiocel or obtaining additional financing, which may be difficult given competitive environment and lack of approved products."]
Competitors & peers
- Sarepta Therapeutics (SRPT)
- Solid Biosciences (SLDB)
- Editas Medicine (EDIT)
- Acceleron Pharma
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.